ArticleJournal of cellular and molecular medicine2026
Investigation of the Effect of Triacetyl Resveratrol on Epithelial-Mesenchymal Transition in Human Lung Cancer Cell Lines.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Investigation of the Effect of Triacetyl Resveratrol on Epithelial-Mesenchymal Transition in Human Lung Cancer Cell Lines.Journal of cellular and molecular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Our study aimed to investigate the effects of Triacetyl resveratrol (TCRV) on epithelial-mesenchymal transition (EMT) in human lung cancer cell lines. Different concentrations of TCRV were applied to the A549 cell line for 24 and 48 h. The IC50 value of TCRV was determined by cell viability with the CCK-8 test. Expression levels of E-cadherin and vimentin were analysed by immunocytochemistry and qPCR after incubation with TCRV at the determined dose. Apoptosis was assessed by acridine orange/ethidium bromide (AO/EB) staining, and possible interactions of TCRV with target proteins were evaluated by in silico molecular docking. Morphological changes were observed in A549 cells application with the IC50 dose of TCRV, showing decreased cell integrity and altered morphology compared to controls. While E-cadherin and vimentin levels decreased in 24-h application, an increase in both markers was observed in 48-h application. It was determined by the AO/EBr staining method that TCRV significantly increased apoptosis and, according to the in silico molecular docking results, TCRV showed a strong binding tendency with E-cadherin and vimentin. It was demonstrated that TCRV exhibits time-dependent antiproliferative, apoptotic and EMT-regulating effects in A549 cells. While significant anti-proliferative and cytotoxic effects were observed in short-term applications, cellular restructuring and EMT-like processes were triggered along with resistance development in some cells in long-term applications; however, increased stress and apoptosis were determined in the general cell population. Molecular modelling results indicate that TCRV exhibits a strong binding affinity for E-cadherin (-7.00 kcal/mol) and vimentin (-7.70 kcal/mol) at the structural level; however, while these binding data reflect the possibility of direct protein interactions, it should not be overlooked that TCRV may play an active role in the regulation of indirect regulatory mechanisms, such as transcriptional changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.